

Haematologica
HAEMATOL/2017/187153
Version 3

Clofarabine, high-dose cytarabine and liposomal daunorubicin in pediatric relapsed/refractory acute myeloid leukemia: a phase IB study

Natasha K.A. van Eijkelenburg, Mareike Rasche, Essam Ghazaly, Michael N. Dworzak, Thomas Klingebiel, Claudia Rossig, Guy Leverger, Jan Stary, Eveline S.J.M. de Bont, Dana A. Chitu, Yves Bertrand, Benoit Brethon, Brigitte Strahm, Inge M. van der Sluis, Gertjan J.L. Kaspers, Dirk Reinhardt, and C. Michel Zwaan

Disclosures: Conflict-of-interest disclosure: D.R. has consulting or advisory roles for Celgene, Pfizer, MSD, Astellas Pharma, Novartis, and Boehringer, receives research funding from Celgene and receives travel, accommodations or expenses from JAZZ pharmaceutical, NOVO Nordisk and Girfols. C.M.Z. has consulting or advisory roles for Pfizer, Daiichi Sankyo, Celgene, Novartis, Bristol-Myers Squibb, and Gilead Sciences and receives research funding from Karyopharm Therapeutics, Pfizer, BristolMyers Squibb, and GlaxoSmithKline. C.R. has consulting or advisory roles for Pfizer, Amgen, and Genentech. B.B. receives travel, accommodations or expenses from Amgen. T.K. has consulting or advisory roles for Loxo and Pfizer. The remaining authors declare no competing financial interests

Contributions: Contribution: C.M.Z., D.R., and E.G conceived and designed the study. C.M.Z. and D.R. provided financial and administrative support; C.M.Z., D.R., M.N.D., T.K., C.R., E.S.J.M.d.B., B.S., I.M.v.d.S., and G.J.L.K. provided study materials or patients; N.v.E., M.R., E.G., M.D., T.K., C.R., G.L., J.S., E.S.J.M.d.B., D.C., B.B., B.S., G.J.L.K., C.M.Z. and D.R., collected and assembled data; N.v.E., M.R., E.G., D.C., C.M.Z. and D.R., analyzed and interpreted data; N.v.E and M.R. wrote the manuscript; and all authors gave final approval of manuscript.